<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40240267</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2255-534X</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Revista de gastroenterologia de Mexico (English)</Title><ISOAbbreviation>Rev Gastroenterol Mex (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Treatment of small intestinal bacterial overgrowth in Chilean patients with irritable bowel syndrome: A prospective and comparative study.</ArticleTitle><Pagination><StartPage>54</StartPage><EndPage>62</EndPage><MedlinePgn>54-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rgmxen.2024.08.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2255-534X(25)00002-7</ELocationID><Abstract><AbstractText Label="INTRODUCTION AND AIM" NlmCategory="OBJECTIVE">Patients with disorders of the gut-brain axis, such as irritable bowel syndrome (IBS), often exhibit small intestinal bacterial overgrowth (SIBO). Its treatment includes rifaximin (RF), ciprofloxacin (CF), neomycin, sulfamethoxazole-trimethoprim, and metronidazole (MZ). RF is a non-absorbable antibiotic, postulated to have fewer adverse effects. Our aim was to assess symptomatic response and SIBO eradication in patients with IBS, using three antibiotic regimens.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective, randomized, double-blind study was conducted on IBS patients over 18 years of age, utilizing the Rome IV questionnaire and lactulose breath test. Those diagnosed with SIBO were randomly assigned to receive antibiotic treatment. Group A was treated with RF, group B with CF, and group C with MZ, each for 10 days. Treatment response was evaluated based on the SIBO eradication rate 15 days after completing therapy, utilizing hydrogen and methane breath tests with lactulose. Self-reported symptoms were recorded on a 10-point Likert scale before, during, and after treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ninety-seven patients with IBS and SIBO were included, 81% of whom completed treatment. Fifty-nine percent of the patients treated with RF achieved SIBO eradication, compared with 53% and 79% of those treated with CR and MZ, respectively. Metronidazole reduced more methane levels, compared with the other groups. However, the greatest reduction in abdominal pain and bloating was observed in the RF group, with a lower percentage of adverse events.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with IBS and SIBO benefit from antibiotic therapy. MZ exhibited the best SIBO eradication rate, but RF demonstrated greater symptomatic improvement and a lower rate of adverse effects.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Asociaci&#xf3;n Mexicana de Gastroenterolog&#xed;a. Published by Masson Doyma M&#xe9;xico S.A. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>von Muhlenbrock</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratorio de Enfermedades Digestivas y Motilidad, Secci&#xf3;n de Gastroenterolog&#xed;a, Hospital Cl&#xed;nico Universidad de Chile, Universidad de Chile, Santiago, Chile; Departamento de Medicina Interna, Centro de Enfermedades Digestivas, Universidad de los Andes, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landskron</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratorio de Enfermedades Digestivas y Motilidad, Secci&#xf3;n de Gastroenterolog&#xed;a, Hospital Cl&#xed;nico Universidad de Chile, Universidad de Chile, Santiago, Chile; Centro de Investigaci&#xf3;n en Biomedicina (CIBMED), Escuela de Medicina, Facultad de Medicina, Universidad Finis Terrae, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madrid</LastName><ForeName>A M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Laboratorio de Enfermedades Digestivas y Motilidad, Secci&#xf3;n de Gastroenterolog&#xed;a, Hospital Cl&#xed;nico Universidad de Chile, Universidad de Chile, Santiago, Chile. Electronic address: amadrid@hcuch.cl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Rev Gastroenterol Mex (Engl Ed)</MedlineTA><NlmUniqueID>101778603</NlmUniqueID><ISSNLinking>2255-534X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005765">Gastrointestinal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>140QMO216E</RegistryNumber><NameOfSubstance UI="D008795">Metronidazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012294">Rifamycins</NameOfSubstance></Chemical><Chemical><RegistryNumber>L36O5T016N</RegistryNumber><NameOfSubstance UI="D000078262">Rifaximin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="Y">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001944" MajorTopicYN="N">Breath Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002677" MajorTopicYN="N" Type="Geographic">Chile</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005765" MajorTopicYN="Y">Gastrointestinal Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007421" MajorTopicYN="Y">Intestine, Small</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008795" MajorTopicYN="N">Metronidazole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012294" MajorTopicYN="N">Rifamycins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078262" MajorTopicYN="N">Rifaximin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001765" MajorTopicYN="Y">Blind Loop Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Breath test</Keyword><Keyword MajorTopicYN="N">Irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Metronidazol</Keyword><Keyword MajorTopicYN="N">Metronidazole</Keyword><Keyword MajorTopicYN="N">Prueba de aliento</Keyword><Keyword MajorTopicYN="N">Rifaximin</Keyword><Keyword MajorTopicYN="N">Rifaximina</Keyword><Keyword MajorTopicYN="N">Small intestinal bacterial overgrowth</Keyword><Keyword MajorTopicYN="N">Sobrecrecimiento bacteriano en intestino delgado</Keyword><Keyword MajorTopicYN="N">S&#xed;ndrome de intestino irritable</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>9</Day><Hour>11</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>17</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>16</Day><Hour>22</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40240267</ArticleId><ArticleId IdType="doi">10.1016/j.rgmxen.2024.08.003</ArticleId><ArticleId IdType="pii">S2255-534X(25)00002-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>